Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listZanubrutinib

Zanubrutinib

  • CAS NO.:1691249-45-2
  • Empirical Formula: C27H29N5O3
  • Molecular Weight: 471.55
  • MDL number: MFCD31567461
  • Update Date: 2024-11-13 18:13:23
Zanubrutinib Structural

What is Zanubrutinib?

Absorption

Following oral administration of zanubrutinib 160 mg twice daily and 320 mg once daily, the mean (%CV) zanubrutinib steady-state concentrations were 2,295 (37%) ng·h/mL and 2,180 (41%) ng·h/mL, respectively. The mean Cmax (%CV) was 314 (46%) ng/mL following 160 mg twice daily and 543 (51%) ng/mL following 320 mg once daily.
The Cmax and AUC of zanubrutinib increase in a dose-proportional manner and there is minimal systemic accumulation after repeated dosing. The median Tmax is 2 hours.

Toxicity

There is limited data on zanubrutinib overdose.

Description

Zanubrutinib, a second-generation BTK inhibitor discovered and developed by BeiGene in China, has been approved by the FDA (in 2019) for treating chronic lymphocytic leukemia (CLL) and certain other indications. Zanubrutinib has lower toxicity and better efficacy than ibrutinib. It is in direct competition with AstraZeneca’s acalabrutinib for the $12 billion blood cancer market currently dominated by the first-in-class BTK inhibitor ibrutinib.

The Uses of Zanubrutinib

Zanubrutinib is classified as a Bruton''s tyrosine kinase inhibitor. Zanubrutinib is a medication for the treatment of adults with mantle cell lymphoma.

Background

Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and proliferation of malignant B cells. Compared to the first-generation BTK inhibitor ibrutinib, zanubrutinib displays higher potency and selectivity for BTK with fewer off-target effects. Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes acalabrutinib, which was approved by the FDA in 2017.
Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL, which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug. It is currently marketed under the trade name BRUKINSA? and is available as oral capsules. In August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenstr?m’s macroglobulinemia. This indication is valid in the US, Europe, and Canada. In September 2021, zanubrutinib was granted another accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended zanubrutinib be granted marketing authorization for the treatment of chronic lymphocytic leukemia.

Indications

Zanubrutinib is indicated for the treatment of:

brand name

BrukinsaTM

General Description

Class: non-receptor tyrosine kinase
Treatment: MCL, MZL, WM
Oral bioavailability = 15%
Elimination half-life = 3.3 h
Protein binding = 94%

Pharmacokinetics

Zanubrutinib is an immunomodulating agent that decreases the survival of malignant B cells. It inhibits BTK by binding to its active site. It works to inhibit the proliferation and survival of malignant B cells to reduce the tumour size in mantle cell lymphoma.

Metabolism

Zanubrutinib is predominantly metabolized by CYP3A4. Its metabolites have not been characterized.

Metabolism

Zanubrutinib showed a mean terminal elimination half-life of approximately 2–4 h (160 or 320 mg, QD) and an estimated oral bioavailability of 15%, relative to 3.9% (fasting state) for ibrutinib. Zanubrutinib is primarily eliminated hepatically via CYP3A4, but its metabolites have not been characterized.

Properties of Zanubrutinib

Boiling point: 713.4±60.0 °C(Predicted)
Density  1.33±0.1 g/cm3(Predicted)
storage temp.  Store at -20°C
solubility  DMSO:99.67(Max Conc. mg/mL);211.36(Max Conc. mM)
DMF:10.0(Max Conc. mg/mL);21.21(Max Conc. mM)
DMF:PBS (pH 7.2) (1:5):0.16(Max Conc. mg/mL);0.34(Max Conc. mM)
Ethanol:33.33(Max Conc. mg/mL);70.68(Max Conc. mM)
form  A solid
pka 15.35±0.40(Predicted)
color  White to off-white

Safety information for Zanubrutinib

Signal word Warning
Pictogram(s)
ghs
Exclamation Mark
Irritant
GHS07
GHS Hazard Statements H302:Acute toxicity,oral
H315:Skin corrosion/irritation
H319:Serious eye damage/eye irritation
H335:Specific target organ toxicity, single exposure;Respiratory tract irritation
Precautionary Statement Codes P261:Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

Computed Descriptors for Zanubrutinib

Related products of tetrahydrofuran

You may like

  • Zanubrutinib 1691249-45-2 99%
    Zanubrutinib 1691249-45-2 99%
    1691249-45-2
    View Details
  • 1691249-45-2 (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide; Zanubrutinib API 98%
    1691249-45-2 (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide; Zanubrutinib API 98%
    1691249-45-2
    View Details
  • Zanubritinib 1691249-45-2 98%
    Zanubritinib 1691249-45-2 98%
    1691249-45-2
    View Details
  • Zanubrutinib 1691249-45-2 98%
    Zanubrutinib 1691249-45-2 98%
    1691249-45-2
    View Details
  • 177-11-7 1,4-Dioxa-8-azaspiro[4.5]decane 98+
    177-11-7 1,4-Dioxa-8-azaspiro[4.5]decane 98+
    177-11-7
    View Details
  • 217299-03-1 98+
    217299-03-1 98+
    217299-03-1
    View Details
  • 4-AMINO-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID 39124-20-4 98+
    4-AMINO-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID 39124-20-4 98+
    39124-20-4
    View Details
  • 39856-50-3 98+
    39856-50-3 98+
    39856-50-3
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.